人脑胶质瘤树突状细胞疫苗的临床应用

目的探讨人脑胶质瘤树突状细胞(DC)疫苗的临床疗效。方法采集患者胶质母细胞瘤手术标本,用热休克诱导肿瘤细胞凋亡,制备符合临床应用的人脑胶质瘤DC疫苗。25例脑胶质瘤患者分为C组(12例)和DC组(13例):C组采用传统的手术及术后放化疗治疗;DC组加用DC疫苗。比较两组肿瘤局部控制率(LCR)、生存时间和生活质量的Karnofsky评级,记录并发症。结果随访2年。治疗结束后9个月时,DC组肿瘤LCR明显高于C组(69.2%vs.25.0%)(P<0.05)。DC组治疗结束后6个月及9个月的Karnofsky评级优于C组。DC组1、2年生存率明显高于C组(69.2%、7.7%vs.41.7%、0)(P<0.05)。DC组的肿瘤复发时间为(11.92±25.31)个月,明显晚于C组的(7.75±4.16)个月(P<0.05)。疫苗接种期间,患者均未出现恶心、呕吐、头痛症状,未观察到关节炎、支气管炎等自身免疫性疾病的发生。结论脑胶质瘤DC疫苗联合术后放化疗,为脑胶质母细胞瘤提供一种更有效的治疗方法。

Clinical application of dendritic cell vaccine of human glioblastoma

Objective To investigate the efficacy of treating human glioblastoma with dendritic cells(DCs) vaccine.Methods A total of 25 fresh human glioblastoma samples was taken during operartion.The apoptosis of DCs then was induced by heat-shock protein.The glioblastoma-DC vaccine was prepared by loading peripheral blood-derived DCs.Twenty-five patients were randomized into two groups of C(12 cases,treated with conventional regime of surgical resection followed by radiochemotherapy) and DC(13 cases,treated with additional DCs vaccine).The local control rate(LCR) of the tumor,Karnofsky grading of live quality,survival rate and complication were evaluated.Results The patients were followed up for two years.At the 9th month after complition of therapy,the LCR of the tumor was higher in group DC than that in group C(69.2% vs.25.0%)(P<0.05).At the 6th and 9th month after completion of therapy,Karnofsky grades were better in group DC than those in group C.The 1-and 2-year survival rates were higher in group DC than those in group C(69.2% and 7.7% vs.41.7% and 0)(P<0.05).The priod of tumor recurrence was longer in group DC than that in group C[(11.92±25.31) months vs.(7.75±4.16) months](P<0.05).There were no DC vaccine-related side effects in group DC.Conclusion Combined use of glioblastoma-DC vaccine and conventional surgery plus radiochemotherapy can provide an effective treatment for the patients with glioblastoma.